Posted by Michael Wonder on 28 Feb 2022
Minimally invasive epilepsy treatment EASEE receives FDA breakthrough device designation
21 February 2022 - Precisis has received breakthrough device designation from the U.S. FDA for its EASEE brain stimulator. FDA’s breakthrough devices program classifies medical devices that have the potential to enable more effective treatment of life-threatening or irreversibly debilitating diseases or conditions.
Precisis is a medical device company developing minimally invasive neurostimulation methods to free epilepsy patients from their seizures.
